Samuel Yamshon1, Jia Ruan2. 1. Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, 1305 York Avenue, New York, NY, 10021, USA. 2. Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, 1305 York Avenue, New York, NY, 10021, USA. jruan@med.cornell.edu.
Abstract
PURPOSE OF REVIEW: IMiDs are a class of biologic agents with immunomodulatory, anti-angiogenic, and direct anti-cancer activities. This review summarizes current data on clinical development and application of IMiDs in non-Hodgkin lymphoma (NHL) subtypes, focusing primarily on lenalidomide, with additional discussion on managing common side effects. RECENT FINDINGS: Improved upon the prototype thalidomide, the second-generation compound lenalidomide has enhanced immunological and anti-cancer properties with fewer side effects, while next-generation small molecule cereblon/E3 ubiquitin ligase modulator CC-122 is in early clinical studies. Lenalidomide is FDA-approved for treatment of relapsed/refractory mantle cell lymphoma as a single agent, as well as in combination with rituximab for R/R follicular lymphoma and marginal zone lymphoma. In addition, numerous clinical trials of lenalidomide, as single agent, in combination with anti-CD20 antibodies, or in combination with chemoimmunotherapy regimens, have shown promise in aggressive and indolent NHL in both the upfront and relapsed/refractory setting. As clinical trials with lenalidomide continue to find success in both indolent and aggressive lymphomas, IMiDs are poised to be important building blocks for combinatorial strategies with antibodies, chemotherapy, novel target agents, and emerging immunotherapy involving immune checkpoint inhibitors and chimeric antigen receptor T cell (CAR-T) therapy. Delineation of treatment-specific and disease-specific biomarkers is an important research objective to gain insight into potential mechanisms of action, and to guide future clinical development.
PURPOSE OF REVIEW: IMiDs are a class of biologic agents with immunomodulatory, anti-angiogenic, and direct anti-cancer activities. This review summarizes current data on clinical development and application of IMiDs in non-Hodgkin lymphoma (NHL) subtypes, focusing primarily on lenalidomide, with additional discussion on managing common side effects. RECENT FINDINGS: Improved upon the prototype thalidomide, the second-generation compound lenalidomide has enhanced immunological and anti-cancer properties with fewer side effects, while next-generation small molecule cereblon/E3 ubiquitin ligase modulator CC-122 is in early clinical studies. Lenalidomide is FDA-approved for treatment of relapsed/refractory mantle cell lymphoma as a single agent, as well as in combination with rituximab for R/R follicular lymphoma and marginal zone lymphoma. In addition, numerous clinical trials of lenalidomide, as single agent, in combination with anti-CD20 antibodies, or in combination with chemoimmunotherapy regimens, have shown promise in aggressive and indolent NHL in both the upfront and relapsed/refractory setting. As clinical trials with lenalidomide continue to find success in both indolent and aggressive lymphomas, IMiDs are poised to be important building blocks for combinatorial strategies with antibodies, chemotherapy, novel target agents, and emerging immunotherapy involving immune checkpoint inhibitors and chimeric antigen receptor T cell (CAR-T) therapy. Delineation of treatment-specific and disease-specific biomarkers is an important research objective to gain insight into potential mechanisms of action, and to guide future clinical development.
Authors: Ethan Toumishey; Angeli Prasad; Greg Dueck; Neil Chua; Daygen Finch; James Johnston; Richard van der Jagt; Doug Stewart; Darrell White; Andrew Belch; Tony Reiman Journal: Cancer Date: 2014-10-29 Impact factor: 6.860
Authors: Dominique Verhelle; Laura G Corral; Kevin Wong; Jessica H Mueller; Laure Moutouh-de Parseval; Kristen Jensen-Pergakes; Peter H Schafer; Roger Chen; Emilia Glezer; Gregory D Ferguson; Antonia Lopez-Girona; George W Muller; Helen A Brady; Kyle W H Chan Journal: Cancer Res Date: 2007-01-15 Impact factor: 12.701
Authors: Nishitha Reddy; Francisco J Hernandez-Ilizaliturri; George Deeb; Mark Roth; Mary Vaughn; Joy Knight; Paul Wallace; Myron S Czuczman Journal: Br J Haematol Date: 2007-11-09 Impact factor: 6.998
Authors: Franck Morschhauser; Olivier Fitoussi; Corinne Haioun; Catherine Thieblemont; Hang Quach; Richard Delarue; Sylvie Glaisner; Jean Gabarre; André Bosly; John Lister; Ju Li; Bertrand Coiffier Journal: Eur J Cancer Date: 2013-05-31 Impact factor: 9.162
Authors: P Martin; S-H Jung; B Pitcher; N L Bartlett; K A Blum; T Shea; E D Hsi; J Ruan; S E Smith; J P Leonard; B D Cheson Journal: Ann Oncol Date: 2017-11-01 Impact factor: 32.976
Authors: Pierre V Candelaria; Miguel Nava; Otoniel Martínez-Maza; Tracy R Daniels-Wells; Manuel L Penichet Journal: J Immunother Date: 2022-04-26 Impact factor: 4.912
Authors: Caner Saygin; Karilyn Larkin; James S Blachly; Shelley Orwick; Apollinaire Ngankeu; Charles T Gregory; Mitch A Phelps; Shylaja Mani; Alison Walker; Ramiro Garzon; Sumithira Vasu; Katherine J Walsh; Bhavana Bhatnagar; Rebecca B Klisovic; Michael R Grever; Guido Marcucci; John C Byrd; William Blum; Alice S Mims Journal: Am J Hematol Date: 2020-09-19 Impact factor: 10.047
Authors: Peter J Cossar; Madita Wolter; Lars van Dijck; Dario Valenti; Laura M Levy; Christian Ottmann; Luc Brunsveld Journal: J Am Chem Soc Date: 2021-05-28 Impact factor: 15.419